Clariant Q3 EBITDA before exceptional items falls 7% to CHF 151.5 million

By Public Technologies
  • Clariant’s third-quarter 2026 EBITDA before exceptional items fell 7% year over year to CHF 151.5 million.
  • Sales rose 7% year over year to CHF 968.8 million.
  • The earnings decline reflected normalized Corporate costs, weaker Catalysts operating leverage, and unfavorable mix and raw-material effects in Care Chemicals and Catalysts.
  • Clariant maintained its 2026 EBITDA margin guidance before exceptional items of around 18%, supported by a strong fourth-quarter order book, particularly in Catalysts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clariant AG published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.